Mycosis Fungoides and the Sézary Syndrome Treatment–for health professionals (PDQ®)

SECTIONS

Changes to This Summary (12/23/2015)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

General Information About Mycosis Fungoides and the Sézary Syndrome

Added Kadin et al. as reference 19.

Stage Information for Mycosis Fungoides and the Sézary Syndrome

Added text to state that recent clinical trials assess the extent of skin involvement using detailed scoring systems such as the modified Severity Weighted Assessment Tool (cited 2011 Olsen et al. as reference 4).

Stage I Mycosis Fungoides

Added Elcin et al. as reference 13. Added Foss et al. as reference 17 and 1995 Olsen et al. as reference 18. Also added that a retrospective review of 198 patients with mycosis fungoides and the Sézary syndrome compared time to next treatment (TTNT) between interferon alpha and conventional chemotherapy (cited Hughes et al. as reference 19 and level of evidence 3iiiDiv). Added that a retrospective review of 198 patients with mycosis fungoides and the Sézary syndrome compared TTNT between histone deacetylase inhibitors (HDACi) and conventional chemotherapy (added level of evidence 3iiiDiv). Added Talpur et al. as reference 28. Added lenalidomide as a treatment option for stage I mycosis fungoides and the Sézary syndrome (cited Querfeld et al. as reference 29).

Stage II Mycosis Fungoides

Added Elcin et al. as reference 10. Added 1995 Olsen et al. as reference 15. Also added text to state that a retrospective review of 198 patients with mycosis fungoides and the Sézary syndrome compared TTNT between interferon alpha and conventional chemotherapy (cited Hughes et al. as reference 16 and level of evidence 3iiiDiv). Added that a retrospective review of 198 patients with mycosis fungoides and the Sézary syndrome compared TTNT between HDACi and conventional chemotherapy (added level of evidence 3iiiDiv). Added Talpur et al. as reference 27. Added lenalidomide as a treatment option for stage II mycosis fungoides and the Sézary syndrome (cited Querfeld et al. as reference 28).

Stage III Mycosis Fungoides

Added Elcin et al. as reference 8. Added text to state that chemotherapeutic agents generally demonstrate short durations of response; in a retrospective review of 198 patients with advanced-stage disease, the median time before patients required new therapy was 4 months (cited Hughes et al. as reference 14). Also added that a retrospective review of 198 patients with mycosis fungoides and the Sézary syndrome compared TTNT between interferon alpha and conventional chemotherapy (added level of evidence 3iiiDiv). Added that a retrospective review of 198 patients with mycosis fungoides and the Sézary syndrome compared TTNT between HDACi and conventional chemotherapy (added level of evidence 3iiiDiv). Added Talpur et al. as reference 33. Added lenalidomide as a treatment option for stage III mycosis fungoides and the Sézary syndrome (cited Querfeld et al. as reference 35).

Stage IV Mycosis Fungoides and the Sézary Syndrome

Added Elcin et al. as reference 8. Added text to state that chemotherapeutic agents generally demonstrate short durations of response; in a retrospective review of 198 patients with advanced-stage disease, the median time before patient required new therapy was 4 months (cited Hughes et al. as reference 13). Also added that a retrospective review of 198 patients with mycosis fungoides and the Sézary syndrome compared TTNT between interferon alpha and conventional chemotherapy (added level of evidence 3iiiDiv). Added that chemotherapeutic agents generally demonstrate short durations of response; in a retrospective review of 198 patients with advanced-stage disease, the median time before patients required new therapy was 4 months. Added that a retrospective review of 198 patients with mycosis fungoides and the Sézary syndrome compared TTNT between HDACi and conventional chemotherapy (added level of evidence 3iiiDiv). Added Talpur et al. as reference 36. Added lenalidomide as a treatment option for stage IV mycosis fungoides and the Sézary syndrome (cited Querfeld et al. as reference 39).

Recurrent Mycosis Fungoides and the Sézary Syndrome

Added Elcin et al. as reference 6. Added that a retrospective review of 198 patients with mycosis fungoides and the Sézary syndrome compared TTNT between HDACi and conventional chemotherapy (cited Hughes et al. as reference 19 and level of evidence 3iiiDiv). Added Talpur et al. as reference 21. Added that chemotherapeutic agents generally demonstrate short durations of response; in a retrospective review of 198 patients with advanced-stage disease, the median time before patients required new therapy was 4 months. Added lenalidomide as a treatment option for recurrent mycosis fungoides and the Sézary syndrome (cited Querfeld et al. as reference 22). Added pegylated liposomal doxorubicin as a treatment option (cited Dummer et al. as reference 23, Wollina et al. as reference 24, and Quereux et al. as reference 25).

This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Recurrent Mycosis Fungoides and the Sézary Syndrome

Next section >
About This PDQ Summary